Review of Chronic Myelogenous Leukemia Patients Treated with Imatinib

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study involves a comprehensive chart review of Chronic Myelogenous Leukemia (CML) patients who have been treated with tyrosine kinase inhibitors like imatinib outside of clinical trials. Researchers will collect demographic data, treatment history, laboratory values, and information on treatment toxicity and pregnancy outcomes. The goal is to better understand the long-term effects and management of CML in a real-world setting, as these patients may differ significantly from those in clinical trials. The study aims to gather data from over 300 patients who have sought second opinions at MD Anderson Cancer Center.

Why it matters

Who can join: the full rules

Inclusion Criteria:

All patients with CML in any phase of the disease (chronic, accelerated or blast phase) that has received treatment with any FDA-approved tyrosine kinase inhibitor (eg, imatinib, dasatinib, nilotinib) not on an MDACC clinical trial regardless of prior treatment history that has had at least one clinic visit at MDACC will be eligible.

Exclusion Criteria:

N/A

Where it's running

• University of Texas MD Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Koji Sasaki, M.D. — M.D. Anderson Cancer Center
• Study coordinator: Koji Sasaki, M.D.
• Email: ksasaki1@mdanderson.org
• Phone: (713) 745-2882

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Velzatinib for advanced GIST after multiple prior TKIs

  This study tests velzatinib to see if it can shrink or slow tumors in people with metastatic or unresectable GIST who have progressed on or could not tolerate standard therapies.

  Recruiting at 3 sites Phase 2 GlaxoSmithKline · Fukuoka and 2 other locations · NCT07689201

• Velzatinib vs. Imatinib as frontline treatment for metastatic or unresectable GIST

  This trial tests velzatinib against imatinib as the first systemic therapy for adults with newly diagnosed metastatic or unresectable gastrointestinal stromal tumors to see if velzatinib can delay progression and be tolerable.

  Recruiting at 93 sites Phase 3 GlaxoSmithKline · Scottsdale, Arizona and 92 other locations · NCT07585266

• Imatinib added to artemether-lumefantrine for uncomplicated P. falciparum malaria

  This trial tests whether adding imatinib to standard artemether-lumefantrine helps people with uncomplicated Plasmodium falciparum malaria clear infections faster and limit drug-resistant parasites.

  Recruiting Phase 2 Victoria Biomedical Research Institute · Kisumu · NCT07559370

• KQB198 plus imatinib for first-line advanced or metastatic GIST

  This Phase 2 test will see if adding the experimental drug KQB198 to imatinib helps people with advanced or metastatic GIST who are starting first-line treatment.

  Recruiting at 17 sites Phase 2 Kumquat Biosciences Inc. · Los Angeles, California and 16 other locations · NCT07406633

• Asciminib for children and teens with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase

  This study will try asciminib as a treatment for children aged 1 to under 18 with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase, including newly diagnosed patients and those who are resistant or intolerant to prior TKIs, with or without the T315I mutation.

  Recruiting at 39 sites Phase 2 Novartis · Chicago, Illinois and 38 other locations · NCT07354074

• IDRX-42 versus sunitinib for adults with advanced gastrointestinal stromal tumors after imatinib

  This test compares IDRX-42 (GSK6042981) with sunitinib in adults with advanced or unresectable GIST who have already been treated with imatinib to see which controls the cancer better and is safer.

  Recruiting at 156 sites Phase 3 GlaxoSmithKline · Phoenix, Arizona and 155 other locations · NCT07218926

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.